| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8443136 | European Journal of Cancer | 2014 | 10 Pages |
Abstract
There was no benefit in terms of OS, PFS or RR for a weekly regimen nor for extended chemotherapy as first-line treatment for EOC in European patients.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
M.E.L. van der Burg, W. Onstenk, I.A. Boere, M. Look, P.B. Ottevanger, D. de Gooyer, L.G.M. Kerkhofs, F.A.A. Valster, J.B. Ruit, A.G.P.M. van Reisen, S.H. Goey, A.M.E. van der Torren, D. ten Bokkel Huinink, T.C. Kok, J. Verweij, H.C. van Doorn,